Navigation Links
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
Date:5/14/2013

gs from 2012-2022 in the US1 Table of Contents1 Table of Contents 41.1 List of Tables 71.2 List of Figures 92 Introduction 102.1 Catalyst 102.2 Related Reports 113 Disease Overview 133.1 Etiology and Pathophysiology 133.1.1 Etiology 133.1.2 Pathophysiology 143.1.3 Classification of Multiple Sclerosis 153.2 Symptoms 173.2.1 Prognosis 183.2.2 Quality of Life 194 Disease Management 204.1 Diagnosis 204.2 Treatment Overview 234.2.1 Management of Acute Relapse 244.2.2 Treatment with Disease-Modifying Therapies 244.2.3 Symptomatic Therapies 274.3 US 284.3.1 Diagnosis 284.3.2 Clinical Practice 295 Competitive Assessment 315.1 Overview 315.2 Strategic Competitor Assessment 325.3 Product Profiles – Major Brands 345.3.1 Betaseron/Betaferon (interferon beta-1b) 345.3.2 Avonex (interferon beta-1a) 395.3.3 Rebif (interferon beta-1a) 445.3.4 Copaxone (glatiramer acetate; copolymer-1) 485.3.5 Tysabri (natalizumab) 525.3.6 Gilenya/Imusera (fingolimod; FTY720) 575.3.7 Aubagio (teriflunomide) 625.3.8 Other Disease–Modifying Therapies 676 Opportunity and Unmet Need 686.1 Overview 686.2 Unmet Needs 696.2.1 Currently Available MS Drugs Only Provide Partial Benefits 696.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 706.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects 716.2.4 Effective Treatments for Progressive MS Are Still Elusive 726.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 736.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis 746.3 Unmet Needs Gap Analysis 756.4 Opportunities 766.4.1 Treatments for Progressive MS 766.4.2 Targeting Patients with Clinically Isolated Syndrome 767 Pipeline Assessment 777.1 Overview 777.2 Promising Drugs in Clinical Development 787.2.1 BG-12 (dimethyl fumarate; BG00012) 817.2.2 Lemtrada (alemtuzumab) 867.2.3 Laquinimod (ABR-215062) 927.2.4 Daclizumab High-Yield Process (HYP) 977.2.5 Ocrelizumab (RG1594) 1027.2.6 Siponimod (BAF-31
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
2. PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
3. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
4. In Relapsed/Refractory Multiple Myeloma, Thought Leaders Are Optimistic that the Combination of Carfilzomib, Lenalidomide and Dexamethasone Will Be the Most Efficacious Regimen
5. Hobart Group Holdings Marks 10th Anniversary With Multiple Milestones
6. Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis
7. For Pharma Companies, Launching Multiple Similar Products Can Be a "Good Problem" but Requires Smart Resourcing
8. Deploying an Effective Pay for Performance Bonus System that Works Across Multiple Industry Sectors
9. Aurigene Announces Transition of Multiple Programs to Clinical Development in its Collaboration Business
10. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
11. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... (Nasdaq: CPHD ) today reported revenues for ... growth of 15% from $100.1 million for the third ... of 2014 was $(7.2) million, or $(0.10) per share, ... $(0.02) per share, in the third quarter of 2013.  ... debt discount and transaction costs, and amortization of purchased ...
(Date:10/16/2014)... 2014 Eight finalists, all representing outstanding innovation ... their proposals for a chance to compete for one ... Zayed Institute Second Annual Pediatric Surgical Innovation Symposium ... Friday, Oct. 24, 2014. Selected from a ... US and internationally, the finalists are: ...
(Date:10/16/2014)... , Oct. 16, 2014 Curtis & Coulter ... 3 weeks away from hosting their co-located Bioequivalence: ... Oral Drug Formulation Innovations Summit taking place on ... Diego, CA. November,s events are ... in streamlining the bioequivalence testing process, as well as ...
Breaking Medicine Technology:Cepheid Reports 2014 Third Quarter Results 2Cepheid Reports 2014 Third Quarter Results 3Cepheid Reports 2014 Third Quarter Results 4Cepheid Reports 2014 Third Quarter Results 5Cepheid Reports 2014 Third Quarter Results 6Cepheid Reports 2014 Third Quarter Results 7Cepheid Reports 2014 Third Quarter Results 8Cepheid Reports 2014 Third Quarter Results 9Cepheid Reports 2014 Third Quarter Results 10Cepheid Reports 2014 Third Quarter Results 11Cepheid Reports 2014 Third Quarter Results 12Cepheid Reports 2014 Third Quarter Results 13Cepheid Reports 2014 Third Quarter Results 14Cepheid Reports 2014 Third Quarter Results 15Cepheid Reports 2014 Third Quarter Results 16Cepheid Reports 2014 Third Quarter Results 17Finalists for Children's National Health System pediatric medical device competition announced 2Finalists for Children's National Health System pediatric medical device competition announced 3Finalists for Children's National Health System pediatric medical device competition announced 4Simplifying the Bioequivalence Testing Process and Optimizing Oral Formulation Development via Unifying the Global Life Science Community this November in San Diego 2
... PORTSMOUTH, N.H., Aug. 4, 2011 Novocure, a ... it has entered into a long-term supply agreement ... engineering and manufacturing conglomerate ITT Corporation (NYSE: ITT). ... ceramic components used to manufacture the disposable electrodes ...
... Texas, Aug. 4, 2011 Healthpoint Biotherapeutics today ... clinical trial investigating the efficacy of HP802-247 in ... living cell suspension containing keratinocytes and fibroblasts. The ... of two cell concentrations and two dosing frequencies ...
Cached Medicine Technology:Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 2Novocure Announces Long-Term Supply Agreement With ITT Corporation for Ceramic Sensor Technology 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 2Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 3Positive Results for Phase IIb Trial of Unique Cell-Based Therapy in Venous Leg Ulcers 4
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses ... long evening dresses . All the company’s old ... current discount is up to 66 percent off. ... the fashion field. Its dress specialists are striving to ... parts of the world. All the company’s items are ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
(Date:10/19/2014)... The federal litigation involving GranuFlo ... forward in Massachusetts federal court, where more than ... dialysis medication, Bernstein Liebhard LLP reports. , ... 2,127 claims now filed over GranuFlo and NaturaLyte ... District Court, District of Massachusetts. Plaintiffs in these ...
(Date:10/19/2014)... DENVER (October 20, 2014) - As Alaska ... the outright legalization of recreational marijuana for adults, Ryan ... in those states and elsewhere in America: make sure ... chaos. , Fox is founder and CEO of The ... first recreational dispensaries. , The Grass Station also ...
(Date:10/19/2014)... October 19, 2014 According to the ... the vast majority of adults (up to 90 ... in their lives, spending at least $50 billion on ... includes; spinal instability, stenosis, spondylolisthesis, and symptomatic degenerative disc ... wear and tear associated with the aging process, but ...
Breaking Medicine News(10 mins):Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 3Health News:More than 2,100 GranuFlo Lawsuits Now Filed in Federal Dialysis Drug Litigation, Bernstein Liebhard LLP Reports 4Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 2Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 3Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 2Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 3Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 4Health News:Santa Rosa Orthopaedic (SRO) Opens the Total Spine Health Program in the North Bay – Offering Quality Care for Low Back Pain 5
... a special protein responsible for cell development (Notch) ... new study shows. ,“Breast cancer cells ... by commonly used hormonal therapy, by increasing the ... Miele, professor, departments of pathology, pharmacology and experimental ...
... basis of recent studies that the commonly employed //chemotherapy ... ,AC/T, a widely accepted chemotherapy might be ... which has been proven to be more efficient in ... also has been proven to be far superior to ...
... doctoral thesis from Karolinska Institutet, our everyday environments are ... degrees when inhaled. Particularly damaging to our cellular DNA ... Sweden. ,"Luckily, most of them do ... time," says scientist Hanna Karlsson. "However, particle levels are ...
... developed a new anti-aging ingredient known as GGC, which ... early next year. // ,GGC is a precursor ... a broad range of potential health benefits. Glutathione is ... in cancer, diabetes, aging and other diseases and degenerative ...
... Madhya Pradesh took part in an AIDS awareness campaign and ... ,The students tied 'suraksha bandhan' (protection bands) on ... their commitment to spread this awareness. ,The students ... of Journalism here as part of a 'Unite for Children, ...
... frozen ready meals including 20 Asda own brand, 4 Sainsbury’s ... may contain small pieces of glass. Customers are also being ... ,The products came from Rye Valley Foods in Carrickmacross, a ... the country's biggest food processors. The company said pieces of ...
Cached Medicine News:Health News:Study Identifies Mechanism Which May Help Tamoxifen Work Better 2Health News:Underground Air - Associated With - DNA Damages 2
... This functional brace is designed for the ... and fibula. The preformed design provides post ... removal of internal or external fixation. The ... and below the fracture site, increasing vascularity ...
... Brace features a multi-axial hinge that duplicates ... altering kinematics. The infinite degree of adjustment ... and extension control of the knee. , ... tibia in correct anatomical alignment. The precision ...
... is a revolutionary cast replacement system for ... leg and foot. , ,A self-adjusting ... and in conjunction with a rigid lattice ... time of fracture or rupture healing can ...
... the constant demands of mobilizing patients quickly. ... necessary to fit bilateral KAFO's.,The complete kit ... knee joints , 4 Copolymer thigh support ... bands , Ortho-wick™ Padding for thigh , ...
Medicine Products: